<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39384777</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Genome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank.</ArticleTitle><Pagination><StartPage>8739</StartPage><MedlinePgn>8739</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8739</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-52890-6</ELocationID><Abstract><AbstractText>Understanding the genetic basis of COVID-19 vaccine seroconversion is crucial to study the role of genetics on vaccine effectiveness. In our study, we used UK Biobank data to find the genetic determinants of COVID-19 vaccine-induced seropositivity and breakthrough infections. We conducted four genome-wide association studies among vaccinated participants for COVID-19 vaccine seroconversion and breakthrough susceptibility and severity. Our findings confirmed a link between the HLA region and seroconversion after the first and second doses. Additionally, we identified 10 genomic regions associated with breakthrough infection (SLC6A20, ST6GAL1, MUC16, FUT6, MXI1, MUC4, HMGN2P18-KRTCAP2, NFKBIZ and APOC1), and one with breakthrough severity (APOE). No significant evidence of genetic colocalisation was found between those traits. Our study highlights the roles of individual genetic make-up in the varied antibody responses to COVID-19 vaccines and provides insights into the potential mechanisms behind breakthrough infections occurred even after the vaccination.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alcalde-Herraiz</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Català</LastName><ForeName>Martí</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Institut de Recerca de la Sida IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xie</LastName><ForeName>JunQing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0040-0042</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="Y">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069078" MajorTopicYN="Y">Seroconversion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097849" MajorTopicYN="N">UK Biobank</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>D.P.A.’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA’s department. R.P. has participated in advisory boards for Pfizer, Gilead, MSD, GSK, Atea, Lilly, Roche, Astra-Zeneca, ViiV Healthcare and Theratechnologies, has participated in lectures and seminars funded by Gilead, Pfizer, GSK and AstraZeneca, and has received research funds awarded to his institution from Gilead, Pfizer, and MSD. All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384777</ArticleId><ArticleId IdType="pmc">PMC11464770</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-52890-6</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-52890-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cai, C. et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol. Ther.29, 2794–2805 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342868</ArticleId><ArticleId IdType="pubmed">34365034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ373, n1088 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappadona, C., Rimoldi, V., Paraboschi, E. M. &amp; Asselta, R. Genetic susceptibility to severe COVID-19. Infect., Genet. Evol.110, 105426 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10022467</ArticleId><ArticleId IdType="pubmed">36934789</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira, E. et al. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature617, 764–768 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10208981</ArticleId><ArticleId IdType="pubmed">37198478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira, L. C., Gomes, C. E. M., Rodrigues-Neto, J. F. &amp; Jeronimo, S. M. B. Genome-wide association studies of COVID-19: connecting the dots. Infect. Genet. Evol.106, 105379 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9584840</ArticleId><ArticleId IdType="pubmed">36280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshetie, S., Jullian, P., Benyamin, B. &amp; Lee, S. H. Host genetic determinants of COVID-19 susceptibility and severity: a systematic review and meta-analysis. Rev. Med Virol.33, e2466 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37303119</ArticleId></ArticleIdList></Reference><Reference><Citation>D, E. et al. Genomewide association study of severe Covid-19 with respiratory failure. N. Engl. J. Med.383, 1522–1534 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kousathanas, A. et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature607, 97–103 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259496</ArticleId><ArticleId IdType="pubmed">35255492</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibord, F., Chan, M. V., Chen, M. H. &amp; Johnson, A. D. A year of COVID-19 GWAS results from the GRASP portal reveals potential genetic risk factors. Hum. Genet. Genom. Adv.3, 100095 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863308</ArticleId><ArticleId IdType="pubmed">35224516</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton, J. F. et al. Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat. Genet.53, 801–808 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33888907</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi, M. E. K. et al. Mapping the human genetic architecture of COVID-19. Nature600, 472–477 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak, G. A. et al. A first update on mapping the human genetic architecture of COVID-19. Nature608, E1–E10 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352569</ArticleId><ArticleId IdType="pubmed">35922517</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz, J. E. et al. Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nat. Genet.54, 382–392 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005345</ArticleId><ArticleId IdType="pubmed">35241825</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran, B. Immunology taught by vaccines. Science366, 1074–1075 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196409</ArticleId><ArticleId IdType="pubmed">31780544</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran, B. &amp; Davis, M. M. The science and medicine of human immunology. Science369, eaay4014 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7872131</ArticleId><ArticleId IdType="pubmed">32973003</ArticleId></ArticleIdList></Reference><Reference><Citation>Dendrou, C. A., Petersen, J., Rossjohn, J. &amp; Fugger, L. HLA variation and disease. Nat. Rev. Immunol.18, 325–339 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29292391</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentzer, A. J. et al. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nat. Med.29, 147–157 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873562</ArticleId><ArticleId IdType="pubmed">36228659</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, J. et al. Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes. Nat. Commun.15, 4031 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11091043</ArticleId><ArticleId IdType="pubmed">38740772</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuille-Dit-Bille, R. N. et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids47, 693–705 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25534429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba, K., Imai, Y., Ohto-Nakanishi, T. &amp; Penninger, J. M. Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharm. Ther.128, 119–128 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112678</ArticleId><ArticleId IdType="pubmed">20599443</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydell, G. E., Kindberg, E., Larson, G. &amp; Svensson, L. Susceptibility to winter vomiting disease: a sweet matter. Rev. Med. Virol.21, 370–382 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22025362</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurya, R. et al. Human‐host transcriptomic analysis reveals unique early innate immune responses in different sub‐phenotypes of COVID‐19. Clin. Transl. Med.12, e856 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9191825</ArticleId><ArticleId IdType="pubmed">35696527</ArticleId></ArticleIdList></Reference><Reference><Citation>Camblor, D. G. et al. Genetic variants in the NF-κB signaling pathway (NFKB1, NFKBIA, NFKBIZ) and risk of critical outcome among COVID-19 patients. Hum. Immunol.83, 613–617 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212649</ArticleId><ArticleId IdType="pubmed">35777990</ArticleId></ArticleIdList></Reference><Reference><Citation>Raïch-Regué, D. et al. Role of Siglecs in viral infections: a double-edged sword interaction. Mol. Asp. Med.90, 101113 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9923124</ArticleId><ArticleId IdType="pubmed">35981912</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Zsolt, D. et al. SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. Cell Mol. Immunol.18, 2676–2678 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8591443</ArticleId><ArticleId IdType="pubmed">34782760</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of alzheimer’s disease in late onset families. Science261, 921–3 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging (NIH). Alzheimer’s Disease Genetics Fact Sheet. https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/alzheimers-disease-genetics-fact-sheet#:~:text=One%20well%2Dknown%20gene%20that,to%20the%20development%20of%20Alzheimer’s.</Citation></Reference><Reference><Citation>Xia, X., Wang, Y. &amp; Zheng, J. COVID-19 and Alzheimer’s disease: how one crisis worsens the other. Transl. Neurodegener.10, 15 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8090526</ArticleId><ArticleId IdType="pubmed">33941272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow, C. et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med.12, e1001779 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature562, 203–209 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong, J. et al. Dynamic linkage of covid-19 test results between public health England’s second generation surveillance system and UK biobank. Micro. Genom.6, mgen000397 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478634</ArticleId><ArticleId IdType="pubmed">32553051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbatchou, J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet.53, 1097–1103 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34017140</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, C. C. et al. Second-generation PLINK: Rising to the challenge of larger and richer datasets. Gigascience4, 7 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe, K., Taskesen, E., Van Bochoven, A. &amp; Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun.8, 1826 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705698</ArticleId><ArticleId IdType="pubmed">29184056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace, C. Statistical testing of shared genetic control for potentially related traits. Genet. Epidemiol.37, 802–13 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158901</ArticleId><ArticleId IdType="pubmed">24227294</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet10, e1004383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham, H., François, R., Henry, L., Müller, K. &amp; Vaughan, D. dplyr: A Grammar of Data Manipulation. R package version 1.1.4, https://github.com/tidyverse/dplyr, https://dplyr.tidyverse.org (2023).</Citation></Reference><Reference><Citation>Alcalde-Herraiz, M. oxford-pharmacoepi/GeneticDeterminantsCovid19Vaxs: first_release. GitHub10.5281/zenodo.13309171 (2024).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>